Trials / Not Yet Recruiting
Not Yet RecruitingNCT07363265
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
A Multicenter, Open-label Phase Ⅱ Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Longbio Pharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LP-005 Injection | IV, Q4W |
Timeline
- Start date
- 2026-02-02
- Primary completion
- 2028-08-02
- Completion
- 2029-05-02
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07363265. Inclusion in this directory is not an endorsement.